Literature DB >> 7595650

Proliferative potential of sporadic and neurofibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling.

J Antinheimo1, H Haapasalo, M Seppälä, M Sainio, O Carpen, J Jääskeläinen.   

Abstract

Neurofibromatosis 2 (NF2), a dominantly inherited disorder, is typically manifested as bilateral vestibular Schwannomas and predisposes to other nervous system tumors. Vestibular Schwannomas also occur sporadically but the onset is usually at an older age. Surgical and histological studies have shown that vestibular Schwannomas of NF2 patients are more invasive than sporadic Schwannomas and that the two groups also have morphological differences. We compared the proliferation activity of 26 vestibular Schwannomas (19 NF2 patients) to that of 27 sporadic cases using the Ki-67 (MIB-1) and PCNA (19A2) monoclonal antibodies. In addition, proliferation was assessed in 20 spinal benign Schwannomas, 4 spinal cellular Schwannomas and 3 spinal malignant peripheral nerve sheath tumors (MPNST). We found a significant difference in the proliferation potential between NF2 and sporadic vestibular Schwannomas (MIB-1-LI: 1.72 +/- 0.93 vs 0.95 +/- 0.57, p = 0.001; and PCNA-LI: 1.40 +/- 0.75 vs 0.81 +/- 0.52, p = 0.001). Age does not explain the detected difference in proliferation, since NF2 vestibular Schwannomas also had higher MIB-1 indices than 34 age-matched sporadic tumors. In spinal tumors, MPNST had higher MIB-1 indices than cellular Schwannomas, and therefore MIB-1 staining may be useful in distinguishing between them. Although the defective NF2 gene is important in the tumorigenesis of both NF2 and sporadic Schwannomas, our results suggest that there are differences in the molecular biology of these tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595650     DOI: 10.1097/00005072-199511000-00004

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  6 in total

Review 1.  Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2.

Authors:  M E Baser; V-F Mautner; D M Parry; D G R Evans
Journal:  J Med Genet       Date:  2005-04-14       Impact factor: 6.318

2.  High-resolution array-CGH profiling of germline and tumor-specific copy number alterations on chromosome 22 in patients affected with schwannomas.

Authors:  Teresita Díaz de Ståhl; Caisa M Hansson; Cecilia de Bustos; Kiran K Mantripragada; Arkadiusz Piotrowski; Magdalena Benetkiewicz; Caroline Jarbo; Leif Wiklund; Tiit Mathiesen; Gunnar Nyberg; V Peter Collins; D Gareth Evans; Koichi Ichimura; Jan P Dumanski
Journal:  Hum Genet       Date:  2005-10-28       Impact factor: 4.132

3.  The fate of spinal schwannomas following subtotal resection: a retrospective multicenter study by the Korea spinal oncology research group.

Authors:  Seil Sohn; Chun Kee Chung; Sung-Hye Park; Eun-Sang Kim; Ki-Jeong Kim; Chi Heon Kim
Journal:  J Neurooncol       Date:  2013-06-30       Impact factor: 4.130

4.  Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.

Authors:  Ryota Tamura; Yukina Morimoto; Mizuto Sato; Yuki Kuranari; Yumiko Oishi; Kenzo Kosugi; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2020-01-03       Impact factor: 4.130

5.  [18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.

Authors:  Jose M Anton-Rodriguez; Daniel Lewis; Ibrahim Djoukhadar; David Russell; Peter Julyan; David Coope; Andrew T King; Simon K L Lloyd; D Gareth Evans; Alan Jackson; Julian C Matthews
Journal:  Otol Neurotol       Date:  2019-07       Impact factor: 2.311

6.  Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality.

Authors:  Isabel Gugel; Julian Zipfel; Philip Hartjen; Lan Kluwe; Marcos Tatagiba; Victor-Felix Mautner; Martin Ulrich Schuhmann
Journal:  Childs Nerv Syst       Date:  2020-06-16       Impact factor: 1.475

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.